|
WO2005045436A1
|
|
Diagnostic methods for congestive heart failure
|
|
WO2006032126A1
|
|
Diagnosis and treatment of early pre-type-1 diabetes utilizing neuronal proteins
|
|
EP1631827A1
|
|
Method for identification of glycosylated polypeptides
|
|
EP1562990A2
|
|
Polyclonal-monoclonal elisa assay for detecting n-terminus probnp
|
|
EP1495331A1
|
|
Haptoglobin fragments diagnostic of alzheimers disease
|
|
AU2002336019A1
|
|
Apolipoprotein biopolymer markers predictive of type ii diabetes
|
|
AU2002335966A1
|
|
Plasma protease c1 biopolymer markers predictive of alzheimers disease
|
|
AU2002335969A1
|
|
Complement c3 precursor biopolymer markers predictive of alzheimers disease
|
|
AU2002336842A1
|
|
Hp and apolipoprotein biopolymer markers predictive of alzheimers disease
|
|
WO03046566A2
|
|
Pedf biopolymer markers predictive of alzheimers disease
|
|
AU2002335975A1
|
|
Apolipoprotein biopolymer markers predictive of alzheimers disease
|
|
AU2002335980A1
|
|
Fibrinogen biopolymer marker and its use for the screening of type ii diabetes
|
|
EP1459071A2
|
|
Diagnosis of dementia utilizing thrombospondin
|
|
AU2002335967A1
|
|
Protein biopolymer markers predictive of alzheimers disease
|
|
AU2002335976A1
|
|
Inter alpha trypsin inhibitor biopolymer markers indicative of insulin resistance
|
|
AU2002336845A1
|
|
Globin biopolymer markers indicative of insulin resistance
|
|
AU2002335963A1
|
|
Protein biopolymer markers predictive of alzheimers disease
|
|
US7070945B2
|
|
Process for determining the presence of monomeric brain associated human glutamine synthetase in patients exhibiting mild cognitive impairment
|
|
WO03025577A2
|
|
Diagnosis and treatment of early pre-type 1 diabetes glial fibrillary acidic protein
|
|
US6891154B2
|
|
Amino acid sequence pattern matching
|
